Q2 Earnings Forecast for OPKO Health Issued By HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK) – Stock analysts at HC Wainwright reduced their Q2 2025 EPS estimates for OPKO Health in a research report issued on Monday, March 3rd. HC Wainwright analyst Y. Chen now forecasts that the biotechnology company will post earnings per share of ($0.08) for the quarter, down from their previous forecast of ($0.07). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health’s Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.31) EPS.

Other equities research analysts also recently issued research reports about the company. Barrington Research reiterated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Friday, February 28th. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday.

OPKO Health Stock Performance

NASDAQ:OPK opened at $1.89 on Thursday. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -9.95 and a beta of 1.63. OPKO Health has a twelve month low of $0.86 and a twelve month high of $2.04. The company has a 50-day moving average of $1.57 and a 200-day moving average of $1.56.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The company had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Rubric Capital Management LP grew its holdings in shares of OPKO Health by 9.6% during the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after acquiring an additional 4,284,336 shares in the last quarter. Millennium Management LLC boosted its position in OPKO Health by 85.3% during the fourth quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock valued at $6,745,000 after purchasing an additional 2,112,382 shares during the last quarter. Northern Trust Corp grew its stake in OPKO Health by 4.7% in the fourth quarter. Northern Trust Corp now owns 3,697,774 shares of the biotechnology company’s stock valued at $5,436,000 after purchasing an additional 164,847 shares in the last quarter. Lazard Asset Management LLC increased its position in OPKO Health by 143.6% in the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock worth $3,746,000 after purchasing an additional 1,502,342 shares during the last quarter. Finally, Two Sigma Investments LP raised its stake in shares of OPKO Health by 136.1% during the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock worth $2,422,000 after purchasing an additional 949,671 shares in the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

Insider Activity

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 67,434 shares of the company’s stock in a transaction dated Friday, February 28th. The shares were bought at an average price of $1.71 per share, for a total transaction of $115,312.14. Following the acquisition, the chief executive officer now directly owns 213,301,448 shares of the company’s stock, valued at approximately $364,745,476.08. This trade represents a 0.03 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders acquired 1,389,971 shares of company stock worth $2,124,442 over the last quarter. Corporate insiders own 47.26% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.